• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.

作者信息

Mohan Meera, Rein Lisa E, Thalambedu Nishanth, Ogunsesan Yetunde, Hussain Munawwar, Sethi Jaskirat, Khan Fatima, Gundarlapalli Sravani, Yarlagadda Lakshmi, Dhakal Binod, Price Mary, Shirey Megan, Warner Davie, Thanendrarajan Sharmilan, Janz Siegfried, Radhakrishnan Sabarinath Venniyil, Al Hadidi Samer, Szabo Aniko, D'Souza Anita, Zangari Maurizio, van Rhee Frits, Chhabra Saurabh, Schinke Carolina

机构信息

Division of Hematology/Oncology, Medical College of Wisconsin, Froedtert Clinical Cancer Center, Milwaukee, Wisconsin, USA.

Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

出版信息

Am J Hematol. 2022 Dec;97(12):E451-E453. doi: 10.1002/ajh.26728. Epub 2022 Sep 24.

DOI:10.1002/ajh.26728
PMID:36097868
Abstract
摘要

相似文献

1
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.贝兰他单抗莫福汀的角膜毒性：多机构真实世界经验
Am J Hematol. 2022 Dec;97(12):E451-E453. doi: 10.1002/ajh.26728. Epub 2022 Sep 24.
2
Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma.多发性骨髓瘤患者中贝利司他单抗诱导的角膜变化特征
JAMA Ophthalmol. 2025 May 8. doi: 10.1001/jamaophthalmol.2025.1008.
3
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.EMA 审查贝兰他单抗mafodotin（Blenrep）治疗成人复发/难治性多发性骨髓瘤。
Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23.
4
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.贝兰他单抗mafodotin 与复发/难治性多发性骨髓瘤：游戏尚未结束。
Acta Haematol. 2024;147(4):493-498. doi: 10.1159/000521112. Epub 2021 Nov 26.
5
Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.在多发性骨髓瘤患者中使用红外成像观察与抗体药物偶联物贝兰他单抗莫福汀相关的角膜病变
Cornea. 2025 Feb 1;44(2):196-202. doi: 10.1097/ICO.0000000000003596. Epub 2024 Jun 18.
6
Belantamab mafodotin for the treatment of multiple myeloma.贝兰他单抗马妥昔单抗用于多发性骨髓瘤的治疗。
Drugs Today (Barc). 2021 Nov;57(11):653-663. doi: 10.1358/dot.2021.57.11.3319146.
7
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.贝兰他单抗马妥昔单抗治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂、随机、开放标签、2 期研究。
Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
8
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤患者中贝利司他单抗单药治疗及联合治疗的群体药代动力学
Clin Pharmacokinet. 2025 Jun;64(6):925-942. doi: 10.1007/s40262-025-01508-1. Epub 2025 May 30.
9
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.在复发/难治性多发性骨髓瘤患者中，针对贝兰他单抗mafodotin 的治疗剂量选择进行暴露-反应分析。
Clin Pharmacol Ther. 2021 Nov;110(5):1282-1292. doi: 10.1002/cpt.2409. Epub 2021 Oct 4.
10
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.贝兰他单抗mafodotin 治疗多发性骨髓瘤：临床疗效和安全性概述。
Drug Des Devel Ther. 2021 Jun 2;15:2401-2415. doi: 10.2147/DDDT.S267404. eCollection 2021.

引用本文的文献

1
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience.贝兰他单抗莫福汀治疗复发/难治性多发性骨髓瘤患者：一项真实世界经验。
Blood Neoplasia. 2025 Apr 16;2(3):100103. doi: 10.1016/j.bneo.2025.100103. eCollection 2025 Aug.
2
Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies.与癌症抗体药物偶联物相关的眼部不良事件：证据和管理策略。
Oncologist. 2024 Nov 4;29(11):e1435-e1451. doi: 10.1093/oncolo/oyae177.
3
Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.
在多发性骨髓瘤患者中使用红外成像观察与抗体药物偶联物贝兰他单抗莫福汀相关的角膜病变
Cornea. 2025 Feb 1;44(2):196-202. doi: 10.1097/ICO.0000000000003596. Epub 2024 Jun 18.
4
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.多发性骨髓瘤的免疫治疗：当下现状预示未来发展。
Int J Mol Sci. 2023 Oct 27;24(21):15674. doi: 10.3390/ijms242115674.
5
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.真实世界中贝兰他单抗mafodotin 单药治疗三药难治性多发性骨髓瘤的疗效和安全性。
Int J Mol Sci. 2023 Jul 23;24(14):11829. doi: 10.3390/ijms241411829.
6
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.靶向多发性骨髓瘤患者中的B细胞成熟抗原：当前观点
Onco Targets Ther. 2023 Jun 20;16:441-464. doi: 10.2147/OTT.S370880. eCollection 2023.